Cargando…

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus

We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n=39). Primary endpoint was time to initial treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoo, Soon-Jib, Chang, Sang-Ah, Sohn, Tae Seo, Kwon, Hyuk-Sang, Lee, Jong Min, Moon, Sungdae, Proot, Pieter, Paldánius, Päivi M, Yoon, Kun Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640145/ https://www.ncbi.nlm.nih.gov/pubmed/33176094 http://dx.doi.org/10.4093/dmj.2020.0173

Ejemplares similares

Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin‐metformin combination in newly diagnosed Type 2 diabetes
por: Matthews, D. R., et al.
Publicado: (2019)

Exploring early combination strategy in Latin American patients with newly diagnosed type 2 diabetes: a sub-analysis of the VERIFY study
por: Vencio, Sérgio, et al.
Publicado: (2021)

Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes
por: Matthews, David, et al.
Publicado: (2020)

Research: Treatment Study to determine the durability of glycaemic control with early treatment with a vildagliptin–metformin combination regimen vs. standard-of-care metformin monotherapy—the VERIFY trial: a randomized double-blind trial
por: Del Prato, S, et al.
Publicado: (2014)

Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective
por: Ji, Linong, et al.
Publicado: (2020)

Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
por: Yoon, Kun Ho, et al.
Publicado: (2011)

A pre‐specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM
por: Matthews, David R., et al.
Publicado: (2019)

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes
por: Liu, Jia, et al.
Publicado: (2017)

Lamotrigine monotherapy for newly diagnosed typical absence seizures in children()
por: Holmes, Gregory L., et al.
Publicado: (2008)

Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed type 2 diabetes mellitus: a cohort study
por: Lin, Szu Han, et al.
Publicado: (2018)

Effectiveness and tolerability of perampanel monotherapy in children with newly diagnosed focal epilepsy
por: Zhao, Fen, et al.
Publicado: (2023)

Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy
por: Lindauer, Andreas, et al.
Publicado: (2017)

Efficacy and tolerability of eslicarbazepine acetate as monotherapy in patients of newly diagnosed focal epilepsy
por: Saxena, S., et al.
Publicado: (2021)

Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes
por: Wang, Qiu, et al.
Publicado: (2022)

Raised liver enzymes in newly diagnosed Type 2 diabetes are associated with weight and lipids, but not glycaemic control
por: Saligram, Shreyas, et al.
Publicado: (2012)

Durability of initial antidiabetic monotherapy and subsequent treatment adjustment patterns among newly treated type 2 diabetes patients
por: Noh, Yoojin, et al.
Publicado: (2018)

Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes
por: Ji, Ming, et al.
Publicado: (2016)

Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients
por: Kumar, Surendra
Publicado: (2021)

Body composition in adults with newly diagnosed type 2 diabetes: effects of metformin
por: Aghili, Rokhsareh, et al.
Publicado: (2014)

Secondary Failure of Metformin Monotherapy in Clinical Practice
por: Brown, Jonathan B., et al.
Publicado: (2010)

Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy
por: Yi, Jia-Qin, et al.
Publicado: (2023)

Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma
por: Lee, Nuri, et al.
Publicado: (2021)

A Nation-Wide Epidemiological Study of Newly Diagnosed Primary Spine Tumor in the Adult Korean Population, 2009–2011
por: Sohn, Seil, et al.
Publicado: (2017)

Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
por: Javed, Abid T., et al.
Publicado: (2019)

Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
por: Hur, Kyu Yeon, et al.
Publicado: (2020)

Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
por: Hur, Kyu Yeon, et al.
Publicado: (2020)

HbA(1c) After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes
por: Zeitler, Phil, et al.
Publicado: (2015)

Short term outcomes of topiramate monotherapy as a first-line treatment in newly diagnosed West syndrome
por: Lee, Gyu Min, et al.
Publicado: (2011)

Dual Therapy Appears Superior to Monotherapy for Low-Income Individuals With Newly Diagnosed Type 2 Diabetes
por: Vaughan, Elizabeth M., et al.
Publicado: (2017)

Long‐term safety and efficacy of lacosamide and controlled‐release carbamazepine monotherapy in patients with newly diagnosed epilepsy
por: Ben‐Menachem, Elinor, et al.
Publicado: (2019)

Levetiracetam versus Oxcarbazepine as monotherapy in newly diagnosed focal epilepsy: A systematic review and meta‐analysis
por: Kharel, Sanjeev, et al.
Publicado: (2022)

B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies
por: Anang, Dornatien C, et al.
Publicado: (2022)

Corrigendum: Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy
por: Yi, Jia-Qin, et al.
Publicado: (2023)

The Changes in Early Phase Insulin Secretion in Newly Diagnosed, Drug Naive Korean Prediabetes Subjects
por: Rhee, Sang Youl, et al.
Publicado: (2010)

Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation
por: Paldánius, Päivi Maria
Publicado: (2020)

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
por: Cheng, Lan, et al.
Publicado: (2021)

Predictors of metformin monotherapy failure in gestational diabetes mellitus
por: Benido Silva, Vânia, et al.
Publicado: (2022)

Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer
por: Swofford, Brenen P., et al.
Publicado: (2017)

Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis
por: Kim, Mee Kyoung, et al.
Publicado: (2023)

Clinical characteristics and laboratory findings of children and adolescents who were newly diagnosed with diabetes mellitus
por: Kim, You Jin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ffi3eajug47hndp6qgd16amqd1